Larimar Therapeutics stock plunges after anaphylaxis cases in FA study

Investing.comMonday, September 29, 2025 at 2:58:29 PM
Larimar Therapeutics stock plunges after anaphylaxis cases in FA study
Larimar Therapeutics is facing a significant setback as its stock price plummets following reports of anaphylaxis cases in a recent Friedreich's Ataxia (FA) study. This news is concerning not only for investors but also for patients relying on the company's treatments, highlighting the risks involved in clinical trials and the potential impact on future research and development.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Laidlaw initiates Nasus Pharma stock with Buy rating on anaphylaxis drug
PositiveFinancial Markets
Laidlaw has initiated coverage of Nasus Pharma with a Buy rating for its innovative drug targeting anaphylaxis, a severe allergic reaction that can be life-threatening. This endorsement highlights the potential of Nasus Pharma's product to address a critical medical need, which could lead to increased investor confidence and support for the company's growth. As awareness of anaphylaxis rises, the demand for effective treatments is likely to grow, making this a significant development in the pharmaceutical landscape.
Latest from Financial Markets
Trump renews threat to impose 100% tariffs on non-US made movies
NegativeFinancial Markets
President Trump has reignited his threat to impose 100% tariffs on movies not made in the United States, claiming that the American film-making industry has been 'stolen' by foreign countries. This move could have significant implications for the film industry, potentially raising costs for consumers and affecting international collaborations.
Ormat Technologies stock hits 52-week high at 95.39 USD
PositiveFinancial Markets
Ormat Technologies has reached a significant milestone as its stock price hit a 52-week high of 95.39 USD. This achievement reflects the company's strong performance and investor confidence in its renewable energy solutions. As the demand for sustainable energy sources continues to grow, Ormat's success is a positive indicator for the industry and could attract more investors looking for opportunities in green technology.
Trump administration tightens export controls on Chinese companies
NegativeFinancial Markets
The Trump administration has implemented stricter export controls targeting Chinese companies, particularly affecting subsidiaries of entities that have been blacklisted by the US government. This move is significant as it reflects ongoing tensions between the US and China, impacting trade relations and potentially hindering the operations of affected companies. The tightening of these controls could lead to further economic repercussions and escalate the trade conflict.
Honeywell's West Lays Out Future Energy Needs
PositiveFinancial Markets
In a recent interview, Honeywell's Energy and Sustainability Solutions President & CEO Ken West emphasized the growing demand for energy, predicting that the world will require more power in the future. This insight is crucial as it highlights the need for innovative solutions and sustainable practices to meet increasing energy needs, making it a significant topic for businesses and policymakers alike.
Carnival Q3 2025 presentation slides: Record $2B profit and third guidance raise
PositiveFinancial Markets
Carnival Corporation has reported a record profit of $2 billion for the third quarter of 2025, marking a significant milestone for the cruise line industry. This impressive financial performance not only highlights the company's recovery post-pandemic but also reflects strong consumer demand for travel experiences. Additionally, Carnival raised its guidance for the upcoming quarters, indicating confidence in sustained growth. This news is crucial as it signals a robust rebound in tourism and could positively impact related sectors.
CorVel Corp stock hits 52-week low at $77.64
NegativeFinancial Markets
CorVel Corp's stock has reached a 52-week low, dropping to $77.64, which raises concerns among investors about the company's financial health and market performance. This decline could impact investor confidence and may lead to further scrutiny of CorVel's business strategies and future prospects.